|
|
||||||||
1 Institute for Molecular Medicine and Genetics, 2 Department of Physiology, Medical College of Georgia, Augusta, Georgia 30912; 3 Phoenix Veterans Administration Medical Center, Phoenix 85012; and the 4 Department of Bioengineering, Arizona State University, Tempe, Arizona 85287
| |
ABSTRACT |
|---|
|
|
|---|
Phosphatidylinositol 3-kinase (PI3-kinase) activates protein kinase B (also known as Akt), which phosphorylates and activates a cyclic nucleotide phosphodiesterase 3B. Increases in cyclic nucleotide concentrations inhibit agonist-induced contraction of vascular smooth muscle. Thus we hypothesized that the PI3-kinase/Akt pathway may regulate vascular smooth muscle tone. In unstimulated, intact bovine carotid artery smooth muscle, the basal phosphorylation of Akt was higher than that in cultured smooth muscle cells. The phosphorylation of Akt decreases in a time-dependent manner when incubated with the PI3-kinase inhibitor, LY-294002. Agonist (serotonin)-, phorbol ester (phorbol 12,13-dibutyrate; PDBu)-, and depolarization (KCl)-induced contractions of vascular smooth muscles were all inhibited in a dose-dependent fashion by LY-294002. However, LY-294002 did not inhibit serotonin- or PDBu-induced increases in myosin light chain phosphorylation or total O2 consumption, suggesting that inhibition of contraction was not mediated by reversal or inhibition of the pathways that lead to smooth muscle activation and contraction. Treatment of vascular smooth muscle with LY-294002 increased the activity of cAMP-dependent protein kinase and increased the phosphorylation of the cAMP-dependent protein kinase substrate heat shock protein 20 (HSP20). These data suggest that activation of the PI3-kinase/Akt pathway in unstimulated smooth muscle may modulate vascular smooth muscle tone (allow agonist-induced contraction) through inhibition of the cyclic nucleotide/HSP20 pathway and suggest that cyclic nucleotide-dependent inhibition of contraction is dissociated from the myosin light chain contractile regulatory pathways.
serotonin; phorbol ester; myosin light chains; cAMP-dependent protein kinase
| |
INTRODUCTION |
|---|
|
|
|---|
THE SERINE-THREONINE KINASE Akt was identified as the product of the oncogene v-akt in the lymphomagenic murine retrovirus AKT8 (7). Because of the structural homology to protein kinase A and protein kinase C, Akt is also referred to as protein kinase B and RAC-PK (related to the A and C kinases) (11). Various growth factors activate Akt. Akt is a direct downstream target of phosphatidylinositol 3-kinase (PI3-kinase) and is involved in mediating cell survival and protection from apoptosis (17). Akt has been implicated in other biological actions such as meiosis in oocytes (1), myogenic differentiation (18), and differentiation of adipocytes (20) and several actions of insulin (29). A specific inhibitor of PI3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY-294002) (31), has been used to study the involvement of Akt in various biological functions. Wortmannin, structurally unrelated to LY-294002, also inhibits PI3-kinase (2). However, wortmannin is less specific in that it also inhibits myosin light chain kinase (MLCK) (25) and the phosphorylation of the myosin regulatory light chains [myosin light chain 20 (MLC20)] in vivo (36).
Physiological substrates of Akt include the glycogen synthase kinase
3
(12), BAD [one of the Bcl2 family of proteins
(14)], phosphofructose-2-kinase (15), and a
cyclic nucleotide phosphodiesterase 3B (PDE3B) (19). Akt
phosphorylates PDE3B on serine-273 in response to insulin and activates
it, leading to decreases in cAMP levels in 3T3-L1 adipocytes
(19). Cyclic nucleotide phosphodiesterases are a family of
structurally related enzymes that hydrolyze the nucleotides cAMP and
cGMP, thus inactivating the cyclic nucleotides. Phosphodiesterase 3 (PDE3) activity represents a substantial percentage of total cAMP
phosphodiesterase activity in heart, blood vessels, and platelets
(8). Therapeutically, the PDE3 inhibitors are used as
positive inotropes, vasodilators, and inhibitors of platelet aggregation (6, 8). Molecular cloning has identified two distinct genes that encode PDE3 activity, yielding isozymes PDE3A and
PDE3B. These isozymes are expressed in several tissues, including heart, aorta, liver, kidney, epididymal fat, and vascular smooth muscle
(23).
cAMP and cGMP are second messengers that mediate several biological functions, including vascular smooth muscle relaxation (22, 24) and inhibition of smooth muscle contraction (38). cAMP and cGMP mediate cellular processes through activation of cAMP- and cGMP-dependent protein kinases (PKA and PKG), respectively. Because the activation of smooth muscle contraction is thought to occur through increases in intracellular Ca2+, activation of MLCK, and increases in the phosphorylation of the MLC20, many investigators have focused on mechanisms by which activation of cyclic nucleotides would lead to relaxation by reversing or inhibiting this pathway. However, the existing data suggest that cyclic nucleotide-dependent relaxation is not simply a reversal or inhibition of pathways that activate contraction (27, 38). We and others (4, 5, 27, 38) have recently determined that the small heat shock-related protein, HSP20, is a substrate of PKA and PKG that may directly mediate smooth muscle relaxation, independent of the Ca2+/MLC20 regulatory pathways. Thus we hypothesized that Akt might activate PDE3B in vascular smooth muscle maintaining low levels of cyclic nucleotides. This would facilitate agonist-induced contraction. On the other hand, inhibition of Akt would lead to increases in the levels of cyclic nucleotides, increases in the phosphorylated isoform of HSP20, and inhibition of agonist-induced contraction of vascular smooth muscle.
| |
EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Materials. 12-Deoxyphorbol 13-isobutyrate (PDBu) and serotonin (5-HT) were purchased from LC Services (Woburn, MA). Forskolin and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA)-AM were purchased from Calbiochem (La Jolla, CA), and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY-294002) was purchased from Alexis Biochemicals (San Diego, CA). HEPES was obtained from American Bioanalytical (Natick, MA). Urea, SDS, glycine, and Tris were from Research Organics (Cleveland, OH). Coomassie brilliant blue was from ICN Biomedicals (Aurora, OH). EGTA, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), EDTA, polyoxyethylene-sorbitan monolaurate (Tween 20), and all other reagent-grade chemicals were from Sigma Chemical (St. Louis, MO). The reagents used for electrophoretic analysis were purchased from Bio-Rad (Hercules, CA). Rabbit polyclonal anti-MLC20 antibodies were a gift from Dr. James Stull (University of Texas, Galveston, TX), and rabbit polyclonal anti-HSP20 antibodies were kindly provided by Dr. Kanefusa Kato (Aichi Human Service Center, Aichi, Japan). Anti-Akt and anti-phospho-Akt antibodies were obtained from New England Biolabs (Beverly, MA). Goat anti-rabbit secondary antibodies were from Jackson Immunochemical (West Grove, PA). Protein was estimated by the modified Bradford assay kit from Pierce (Rockford, IL).
Preparation of bovine carotid artery smooth muscle and physiological measurements. Bovine carotid arteries were dissected from fetal calves at a local abattoir (Shapiro's, Augusta, GA), placed directly in HEPES buffer (in mM: 140 NaCl, 4.7 KCl, 1.0 MgSO4, 1.0 NaH2PO4, 1.5 CaCl2, 10 glucose, and 10 HEPES; pH 7.4), and stored at 4°C for 24-72 h. The carotid vessels were dissected free from the adventitia and were opened longitudinally. The endothelium was removed by rubbing the intima with a cotton-tipped applicator. Complete denudation of endothelial cells with this technique has been previously confirmed with scanning electron microscopy (39). Transverse strips, 1.0 mm in width, were cut, and each end was tied to a loop of 3-0 silk. In some cases, rings of bovine carotid artery vessel were cut and endothelium was removed by gently denuding the intimal surface with forceps. The muscle strips were suspended in a muscle bath containing a bicarbonate buffer (in mM: 120 NaCl, 4.7 KCl, 1.0 MgSO4, 1.0 NaH2PO4, 10 glucose, 1.5 CaCl2, and 25 Na2HCO3; pH 7.4), equilibrated with 95% O2-5% CO2, at 37°C. The strips were fixed at one end to a stainless steel wire and attached to a Kent Scientific (Litchfield, CT) force transducer (TRN001) interfaced with a DT2801 analog-to-digital board (Data Translation, Marlboro, MA). Data were acquired with Dasylab software (Dasytec, Amherst, MA). For experiments in Ca2+-free conditions, the muscles were equilibrated in bicarbonate buffer without CaCl2 and containing 4 mM EGTA (an extracellular Ca2+ chelator) and 0.1 mM BAPTA-AM (an intracellular Ca2+ chelator). Depletion of extracellular Ca2+ under these conditions has been previously confirmed by failure of the muscles to contract in response to high extracellular KCl (34). All tissues were allowed to equilibrate for 1 h before the experiment. The strips were contracted with 110 mM KCl (with equimolar replacement of NaCl in bicarbonate buffer), the maximal tension obtained was taken as 100%, and tension obtained with agents (agonists, inhibitors) was determined. Force was converted to stress (105 N/m2): force (g) × 0.0987/area, where area is equal to the wet weight [mg/length (mm at maximal length)] divided by 1.055. Agonists and inhibitors were added directly to the muscle baths.
Immunoblotting for Akt and phospho-Akt. Strips of smooth muscle were treated with 50 µM LY-294002 for different time intervals and frozen in liquid N2 and pulverized. The tissue was solubilized in urea-CHAPS buffer consisting of 9 M urea, 2% CHAPS, and 100 mM dithiothreitol (DTT) followed by centrifugation (14,000 g) to remove insoluble material. Fifty micrograms of protein were resolved by SDS-PAGE using 10% polyacrylamide gels. The proteins were transferred to nitrocellulose membrane and blocked with 5% milk in Tris-buffered saline (TBS)-0.5% Tween 20. Separate blots were incubated with antibodies to Akt or phospho-Akt (1:1,000 dilution in TBS-3% bovine serum albumin) overnight at 4°C. The blots were washed with TBS-Tween 20 five times and incubated with goat anti-rabbit IgG-peroxidase secondary antibodies for 1 h at room temperature. The specific binding was detected using Supersignal chemiluminescent substrate (Pierce) and exposed to film (Kodak XAR-5). Akt and phospho-Akt bands (~59 kDa) were identified by comparisons to the markers provided in the antibody kit and were quantitated densitometrically.
Determination of myosin light chain phosphorylation. The strips of bovine carotid artery were equilibrated in a muscle bath as described above and treated with the appropriate agonists. The strips were snap frozen in dry ice-acetone, and the frozen tissue was pulverized under liquid N2. The frozen samples were placed in a frozen slurry of precipitating solution consisting of 90% acetone, 10% trichloroacetic acid, and 10 mM DTT and then allowed to melt to room temperature. The precipitating solution was removed, and the tissues were washed three times with 90% acetone and 10 mM DTT. The samples were dried, and the pellets were suspended in urea-CHAPS buffer consisting of 9 M urea, 2% CHAPS, and 100 mM DTT and then vortexed to solubilize the proteins. Ten micrograms of protein were diluted with 10 µl of urea sample buffer (6.7 M urea, 18 mM Tris, 20 mM glycine, 9 mM DTT, 4.6% saturated sucrose, and 0.004% bromophenol blue) and separated on glycerol-urea minigels (40% glycerol, 10% acrylamide, 0.5% bisacrylamide, 20 mM Tris, and 22 mM glycine) (26). Electrophoretic transfer of proteins from the gels onto nitrocellulose membranes was carried out in a buffer containing 10 mM Na2HPO4 (pH 7.6) at 25 V for 1.5 h at 20°C. The blot was blocked in 5% nonfat milk in TBS (150 mM NaCl and 10 mM Tris, pH 7.4) for 1 h and then incubated overnight at 4°C with antiserum (1:12,000 dilution in TBS with 3% bovine serum albumin) raised to bovine tracheal smooth muscle MLC20 (26). After a brief rinsing with TBS, the membrane was washed three times with buffer B (TBS containing 0.05% NP-40, 3 mM sodium deoxycholate, and 0.1% SDS), rinsed again with TBS, and incubated in goat anti-rabbit IgG-peroxidase secondary antibodies for 1 h at room temperature. The membrane was washed five times with buffer B and then rinsed with TBS before detection of bands using the Supersignal chemiluminescent substrate (Pierce).
Determination of oxygen consumption. Bovine carotid artery rings were suspended in a muscle bath containing physiological saline solution (PSS) buffer (in mM: 140 NaCl, 5.0 KCl, 1.6 CaCl2, 1.2 MgCl2, 1.2 Na2HPO4, 5.6 D-glucose, 2.0 MOPS, and 0.02 EDTA to chelate trace heavy metals; pH 7.4). The rings were contracted with either potassium PSS (109 mM, prepared by stoichiometric substitution of KCl for NaCl in PSS) or the KCl solution (PSS with a bolus addition of KCl to deliver 100 mM K+). Oxygen consumption [measured as oxygen flux (JO2)] and contractile responses were measured in bovine carotid artery rings placed in a 600-µl airtight chamber containing a Clark-style oxygen electrode (Instech Labs, Plymouth Meeting, PA) and connected to a force transducer (Grass FT03) as previously described (37). Oxygen consumption was calculated from the rate of decline in PO2 divided by the wet weight of the ring. Oxygen consumption rates were determined with a custom data collection system at a rate of five samples per second and reporting an on-line, 2-min interval, averaged JO2 every 10 s. The values are reported as means ± SE of JO2 obtained during a 2-min sampling window. Stress measurements are reported as the force generated and normalized for ring cross-sectional area at a length for optimal force generation (35).
PKA activity assay. Bovine carotid artery smooth muscle strips were treated with 100 µM LY-294002 for different time intervals and snap frozen. Strips were suspended in extraction buffer [in mM: 60 Tris · HCl (pH 7.0), 10 EGTA, 2 EDTA, 10 2-mercaptoethanol, and 0.1 NaF, protease inhibitor cocktail (Sigma Chemical) consisting of 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), trans-epoxysuccinyl-L-leucylamido(4-guanidino) butane (E-64), bestatin, leupeptin, aprotinin, and sodium EDTA] at a concentration of 0.5 mg/ml and then homogenized on ice using a Polytron homogenizer (Brinkman Instruments, Westbury, NY). PKA activity in the homogenates was determined using the SignaTECT PKA assay system from Promega as described by the manufacturer. PKA activity was reported as a percentage of the maximal activity in the presence of 1 mM cAMP.
HSP20 phosphorylation: isoelectric focusing immunoblots. Thirty micrograms of protein were loaded onto 12 × 15-cm slab isofocusing gels consisting of 4% acrylamide, 0.1% piperazine diacrylamide, 9 M urea, 5% ampholines (5 parts 6-8, 3 parts 5-7, and 2 parts 3-10), and 2% CHAPS. The cathode buffer consisted of 20 mM sodium hydroxide, and the anode buffer consisted of 10 mM phosphoric acid. The proteins were focused for 10,000 V · h. The gels were equilibrated in 10 mM Tris (pH 6.8), 3% SDS, 19% ethanol, 4% 2-mercaptoethanol and 0.004% bromophenol blue for 30 min. The gels were then transferred to Immobilon (100 mA) for 12 h. The blots were fixed with 20% methanol, dried, blocked with TBS (10 mM Tris, 150 mM NaCl, and 0.5% Tween 20, pH 7.4) and 5% milk for 1 h, washed three times with TBS, and then probed with anti-HSP20 antibodies (1:1,000 dilution in TBS, 5% milk) for 1 h. The blots were washed six times with TBS, 0.5% Tween 20, and incubated with goat anti-rabbit IgG-peroxidase secondary antibodies for 1 h at room temperature. The specific binding was detected using Supersignal chemiluminescent substrate (Pierce) and exposed to film, and the bands were quantitated densitometrically.
Statistical analysis. Data are presented as means ± SE. Statistical analysis was performed by unpaired Student's t-test or one-way ANOVA followed by Newman-Keul's test for comparing two mean values and multiple means, respectively, with a P value of <0.05 considered significant. Densitometric analysis was performed using Desk Scan II and the software Un-scan-it gel (Silk Scientific). The phosphorylated and nonphosphorylated HSP20 and MLC20 bands were quantitated densitometrically. The relative amounts of the phosphorylated forms of HSP20 and MLC20 over the total amount of HSP20 and MLC20 were calculated and reported.
| |
RESULTS |
|---|
|
|
|---|
Phosphorylation of Akt in vascular smooth muscle.
Because Akt is a downstream substrate of PI3-kinase (10),
we examined the effect of PI3-kinase inhibition by LY-294002 on the
phosphorylation state of Akt. Bovine carotid artery strips were
incubated with LY-294002 (50 µM) for different time intervals, and
the phosphorylation state of Akt was analyzed using a phosphorylation state-specific Akt antibody. Basal phosphorylation of Akt was reduced
in a time-dependent manner on incubation with LY-294002 (Fig.
1, A and B). Basal
phosphorylation of Akt in intact bovine carotid artery smooth muscle
was higher than the phosphorylation observed in cultured vascular
smooth muscle cells (8.1 ± 1.52-fold compared with mesangial
cells and 4.1 ± 0.27-fold compared with rat aortic smooth muscle
cells, respectively, Fig. 1C). 5-HT stimulation (1 µM for
10 min) did not lead to significant increases in the phosphorylation of
Akt in bovine carotid artery smooth muscle (data not shown). It has
been demonstrated earlier that 5-HT does not increase Akt
phosphorylation in rat aortic smooth muscle cells, whereas LY-294002
abolished epidermal growth factor-stimulated Akt phosphorylation
(3)
|
Inhibition of smooth muscle contraction by LY-294002.
Treatment of bovine carotid artery smooth muscle with 5-HT (1 µM) led
to a rapid, sustained contraction (109.14 ± 5.39% of the active
stress KCl response, n = 4; Fig.
2A). Pretreatment of the
muscle strip with LY-294002 (50 µM, 30 min) before 5-HT significantly
inhibited the magnitude of contraction (4.52 ± 3.41% KCl
response; Fig. 2A) in a dose-dependent fashion (Fig. 2,
B and C). Addition of LY-294002 (30 µM)
followed by 5-HT (1 µM) also significantly inhibited contraction
(25.3 ± 2.40% and 22.4 ± 1.90% KCl response at 15 and 30 min, respectively; data not shown). The effect of LY-294002 was
reversible in that the muscle strips contracted to 5-HT (99.08 ± 6.31% KCl response) after washout and equilibration for 2 h (data
not shown).
|
|
|
Effect of PI3-kinase inhibition on MLC20
phosphorylation.
Because the activation of vascular smooth muscle contraction is
associated with increases in intracellular Ca2+, activation
of MLCK, and increases in the phosphorylation of the regulatory
MLC20, we conducted experiments to determine whether inhibition of PI3-kinase led to changes in MLC20
phosphorylation. Stimulation of smooth muscle strips with 5-HT (1 µM
for 2 min) led to increases in MLC20 phosphorylation
(0.50 ± 0.05 mol Pi/mol MLC20; Fig.
5, A and B).
However, preincubation of the smooth muscle strips with LY-294002 (50 µM, 30 min) before stimulation with 5-HT did not significantly
inhibit (0.51 ± 0.03 mol Pi/mol MLC20)
the MLC20 phosphorylation (Fig. 5, A and
B). Thus 5-HT-induced contractile force was inhibited by
LY-294002, but MLC20 phosphorylation was not (Fig.
5C). Similarly, PDBu stimulation induced significant MLC20 phosphorylation to 0.26 ± 0.03 and 0.27 ± 0.03 mol Pi/mol MLC20 in the presence and
absence of LY-294002, respectively (Fig. 5, A and
B).
|
Effect of PI3-kinase inhibition on oxygen consumption.
Due to the relatively slow time course of smooth muscle contraction and
the limited phosphocreatine and glycogen stores, there is a tight
association between increased energy utilization and metabolic recovery
(16). One of the more unique properties of smooth muscle
is an energetic behavior that is well correlated with the extent of
myosin light chain phosphorylation (28). We studied the
energetic state of the carotid artery, oxygen consumption, and the
stress in carotid artery rings stimulated with 5-HT in the absence and
presence of LY-294002. The magnitude of the
JO2 increase with 5-HT stimulation was
similar in the presence (25.7 ± 8.6 nmol
O2 · min
1 · g
1)
or absence of the LY-294002 (26.4 ± 9.1 nmol
O2 · min
1 · g
1), suggesting an equivalent total energetic cost for
5-HT activation of this tissue.
Activation of PKA by LY-294002.
One reported substrate of Akt is PDE3 (19). To determine
whether the inhibition of PI3-kinase inhibited smooth muscle
contraction by increases in cyclic nucleotide levels, we measured the
activity of PKA in the presence and absence of LY-294002 (100 µM).
PKA activity was significantly increased in smooth muscle strips
treated with LY-294002 (Fig. 6).
|
HSP20 phosphorylation.
Both relaxation and inhibition of contraction of carotid artery smooth
muscle is associated with increases in the phosphorylation of the small
heat shock-related protein, HSP20 (5, 27, 38). HSP20 is
also phosphorylated in response to insulin and insulin antagonists in
rat skeletal and smooth muscle (32, 33). Because treatment
of carotid artery smooth muscle with LY-294002 leads to activation of
PKA and PKA phosphorylates HSP20, we examined HSP20
phosphorylation in response to LY-294002. Treatment with LY-294002 led
to significant increases in the phosphorylation of HSP20. These
increases were comparable to those seen after treatment with the
phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (1 mM) and the
PKA activator forskolin (10 µM; Fig.
7).
|
| |
DISCUSSION |
|---|
|
|
|---|
In this study, we observed that there was a significant level of basal phosphorylation of Akt in intact vascular smooth muscles compared with cultured vascular smooth muscle cells (Fig. 1), suggesting a high basal activity of PI3-kinase in intact vascular smooth muscle. Results from this study demonstrated that inhibition of this basal activity by the PI3-kinase inhibitor LY-294002 inhibited the ability of bovine carotid artery smooth muscle to contract in response to various contractile stimuli, even though the stimuli did not involve activation of PI3-kinase. Consequently, we designed experiments to study the effect of LY-294002 on the basal activity of the downstream substrate of PI3-kinase, Akt, and subsequent changes in signaling events downstream of Akt activation.
The basal level of phosphorylation of Akt was inhibited by the PI3-kinase inhibitor, LY-294002 (Fig. 1; Ref. 31). Recently, Akt was determined to activate a phosphodiesterase (19), leading to a decrease in intracellular cyclic nucleotide levels. Because increases in intracellular cyclic nucleotides inhibit contraction of vascular smooth muscle, we examined the effect of LY-294002 on physiological contractile responses and the activation of contractile signaling pathways. Treatment of intact vascular smooth muscles with LY-294002 inhibited agonist (5-HT)-, phorbol ester (PDBu)-, and depolarization (KCl)-induced contractions in a dose-dependent manner (Figs. 2-4). LY-294002 had a maximal effect on 5-HT- and PDBu-induced contractions and partial effects on KCl-induced contractions. This differential effect could be partially explained by the fact that these agents initiate contraction by different mechanisms and depolarization-induced contraction is blocked by cyclic nucleotides less effectively than agonist-induced contraction. 5-HT causes vascular smooth muscle contraction by interacting with cell surface receptors and activating signaling pathways that lead to increases in intracellular Ca2+ and activation of protein kinase C (21). Banes et al. (3) reported that LY-294002 inhibits 5-HT-induced contraction in rat aorta. However, they attributed the inhibition of contraction to the possibility of LY-294002 being a 5-HT2A receptor antagonist. Phorbol esters do not require receptor activation and directly activate protein kinase C. We determined that LY-294002 inhibits contractions elicited by the phorbol ester PDBu. Most investigators have focused on the role of the Ca2+, MLCK, and regulatory myosin light chain phosphorylation pathway of muscle contraction. Interestingly, LY-294002 inhibited contractions induced by depolarization with high K+, which leads to increases in intracellular Ca2+. In addition, LY-294002 also inhibited phorbol ester-induced contractions under conditions in which intra- and extracellular Ca2+ is chelated. Taken together, these data suggest that LY-294002 is inhibiting muscle contraction by activating pathways independent of increases in intracellular Ca2+ and myosin light chain phosphorylation.
To directly determine the effect of LY-294002 on the MLC20/MLCK pathway, we measured the phosphorylation of the regulatory myosin light chains. Increases in MLC20 phosphorylation were similar in response to 5-HT and PDBu in the presence and absence of LY-294002 (Fig. 5). Thus there were similar increases in MLC20 phosphorylation under conditions in which stress was present (agonist alone) and absent (LY-294002 before agonist). Finally, we examined the energetic response of the bovine carotid smooth muscle during 5-HT stimulation in the presence and absence of LY-294002. The JO2 served as an indirect measure of the activation state of the tissue reflecting a combination of cross-bridge ATPase activity and the oxidative energy necessary to activate the tissue (e.g., regulatory myosin light chain phosphorylation/dephosphorylation) (37). This suggests that the energetic consequences of 5-HT stimulation are equivalent in both the presence and absence of LY-294002. When viewed with the myosin light chain phosphorylation measurements, we postulate that the impaired force generation ability seen in the presence of LY-294002 relies on a mechanism that does not impair the tissue activation pathway that utilizes light chain phosphorylation and thus cross-bridge cycling. Because energy demands for cross-bridge ATPase activity and myosin light chain phosphorylation can be nearly equivalent at high levels of phosphorylation (37), the substantial energetic cost seen here could account for the moderate levels of phosphorylation. This would be expected if the proposed relaxation mechanism were working by a process independent of myosin phosphorylation and cross-bridge cycling.
To determine whether inhibition of the PI3-kinase/Akt pathway in vascular smooth muscle inhibits contractile responses through the cyclic nucleotide-dependent signaling pathway, we measured the activity of PKA. Treatment of vascular smooth muscle with LY-294002 increased PKA activity (Fig. 6). Because the only known activators of PKA are cyclic nucleotides, this provides indirect evidence that inhibition of PI3-kinase leads to increases in intracellular cyclic nucleotide concentrations. It is likely that the increase in basal concentration of cyclic nucleotides in response to LY-294002 also leads to activation of PKG, since cross-activation of PKG by cAMP during vascular smooth muscle relaxation is possible and has been demonstrated previously by several investigators (22). The specific mechanisms by which activation of cyclic nucleotide-dependent protein kinases leads to vasorelaxation and inhibition of contraction are not known. However, recent attention has been focused on HSP20. HSP20 is phosphorylated in vascular smooth muscle in response to activation of cyclic nucleotide-dependent signaling pathways (5). In addition, HSP20 is not phosphorylated in a muscle that is uniquely refractory to cyclic nucleotide-dependent relaxation, the human umbilical smooth muscle (9). HSP20 can be phosphorylated in vitro by both PKA and PKG (5). The physiologically relevant site of phosphorylation on HSP20 appears to be serine-16 (4). Transient permeabilization of vascular smooth muscle and the introduction of phosphopeptide analogs of HSP20 inhibit agonist-induced contractions of the muscles (4). In this study, we demonstrate that inhibition of PI3-kinase with LY-294002 also leads to increases in the phosphorylation of the PKA substrate HSP20 (Fig. 7).
Taken together, these data suggest that the basal activity of
PI3-kinase is necessary for contraction of vascular smooth muscle by
contractile agents. The physiological consequences of this pathway
appear to be the lowering of intracellular cyclic nucleotide levels to
allow agonist-induced contraction to occur (Fig.
8). Finally, the results of this study
suggest that inhibition of the basal activation of PI3-kinase/Akt
pathway leads to activation of the cyclic nucleotide-dependent
signaling pathway with subsequent increases in the phosphorylation of
HSP20. The cyclic nucleotide pathway inhibits agonist-induced
contraction in a manner that is dissociated from the
MLCK/MLC20 pathway in that force generation is inhibited
but myosin light chain phosphorylation and energy consumption are not.
Although the mechanisms by which phosphorylated HSP20 inhibits the
generation of force are not known, it is interesting to speculate that
HSP20 may be directly interacting with specific, but as yet not
defined, elements of the contractile machinery. Because PDE3 inhibitors
are used as positive inotropes, vasodilators, and inhibitors of
platelet aggregation, manipulation of PDE activity and cAMP levels
through this pathway may have therapeutic potential in the treatment of
vasospastic disorders.
|
| |
ACKNOWLEDGEMENTS |
|---|
We thank Drs. James Stull and Kanefusa Kato for generously supplying antibodies, Dr. Kristine Kamm for the advice on myosin light chain phosphorylation, and Shapiro's Meatpackers for bovine carotid arteries.
| |
FOOTNOTES |
|---|
This work was supported by a Veterans Affairs Merit Review Award and National Heart, Lung, and Blood Institute Grant RO1 HL-58027-01 (to C. M. Brophy) and by American Heart Association, Southest Affiliate, and National Heart Foundation Awards (to C. J. Wingard).
Address for reprint requests and other correspondence: C. M. Brophy, Phoenix VAMC, 650 E. Indian School Rd. CS112, Phoenix, AZ 85012 (E-mail: colleen.brophy{at}med.va.gov).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 23 March 2001; accepted in final form 22 June 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Anderson, CB,
Roth RA,
and
Conti M.
Protein kinase B/Akt induces resumption of meiosis in Xenopus oocytes.
J Biol Chem
273:
18705-18708,
1998
2.
Arcaro, A,
and
Wyman MP.
Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5 trisphosphate in neutrophil responses.
Biochem J
296:
297-301,
1993.
3.
Banes, A,
Florian JA,
and
Watts SW.
Mechanisms of 5-hydroxytryptamine2A receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle.
J Pharmacol Exp Ther
291:
1179-1187,
1999
4.
Beall, A,
Bagwell D,
Woodrum DA,
Stoming TA,
Kato K,
Suzuki A,
Rasmussen H,
and
Brophy CM.
The small heat shock-related protein, HSP20, is phosphorylated on serine 16 during cyclic nucleotide-dependent relaxation.
J Biol Chem
274:
11344-11351,
1999
5.
Beall, AC,
Kato K,
Goldenring JR,
Rasmussen H,
and
Brophy CM.
Cyclic nucleotide-dependent vasorelaxation is associated with the phosphorylation of a small heat shock-related protein.
J Biol Chem
272:
11283-11287,
1997
6.
Beavo, JA.
Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms.
Physiol Rev
75:
725-748,
1995
7.
Bellacosa, A,
Testa JR,
Staal SP,
and
Tsichlis PN.
A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region.
Science
254:
274-277,
1991
8.
Bolger, G,
Michaeli T,
Martins T,
St. John T.,
Steiner B,
Rodgers L,
Riggs M,
Wigler M,
and
Ferguson K.
A family of human phosphodiesterases homologues to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs.
Mol Cell Biol
13:
6558-6571,
1993
9.
Brophy, CM,
Beall A,
Lamb S,
Dickinson M,
and
Ware DJ.
Small heat shock proteins and vasospasm in human umbilical artery smooth muscle.
Biol Reprod
57:
1354-1359,
1997[Abstract].
10.
Coffer, PJ,
Jin J,
and
Woodgett JR.
Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation.
Biochem J
335:
1-13,
1998.
11.
Coffer, PJ,
and
Woodgett JR.
Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families.
Eur J Biochem
201:
475-481,
1991[Web of Science][Medline].
12.
Cross, DAE,
Alessi DR,
Cohen P,
Andjelkovich M,
and
Hemmings BA.
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.
Nature
378:
785-789,
1995[Medline].
13.
Danthuluri, NR,
and
Deth RC.
Phorbol ester induced contraction of arterial smooth muscle and inhibition of
-adrenergic response.
Biochem Biophys Res Commun
125:
1103-1109,
1984[Web of Science][Medline].
14.
Datta, SR,
Dudek H,
Tao X,
Masters S,
Fu H,
Gotoh Y,
and
Greenberg ME.
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.
Cell
91:
231-241,
1997[Web of Science][Medline].
15.
Deprez, J,
Vertommen D,
Alessi DR,
Hue L,
and
Rider MK.
Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades.
J Biol Chem
272:
17269-17275,
1997
16.
Hellstrand, P.
Energetics of smooth muscle contraction.
In: Biochemistry of Smooth Muscle Contraction, edited by Barany M.. San Diego, CA: Academic, 1996, p. 379-392.
17.
Hemmings, BA.
Akt signaling: linking membrane events to life and death decisions.
Science
275:
628-630,
1997
18.
Jiang, B-H,
Aoki M,
Zheng JZ,
Li Z,
and
Vogt PK.
Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B.
Proc Natl Acad Sci USA
96:
2077-2081,
1999
19.
Kitamura, T,
Kitamura Y,
Kudora S,
Hino Y,
Ando M,
Kotani K,
Konishi H,
Matsuzaki H,
Kikkawa U,
Ogawa W,
and
Kasuga M.
Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt.
Mol Cell Biol
19:
6286-6296,
1999
20.
Kohn, AD,
Summers SA,
Birnbaum MJ,
and
Roth RA.
Expression of constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation.
J Biol Chem
271:
31372-31378,
1996
21.
Kotlikoff, MI,
Herrera G,
and
Nelson MT.
Regulation of cytosolic-calcium in smooth muscle.
In: Reviews of Physiology Biochemistry and Pharmacology, edited by Murphy RA.. Berlin: Springer-Verlag, 1999, p. 147-201.
22.
Lincoln, TM.
Cyclic GMP: Biochemistry, Physiology and Pathophysiology. Austin, TX: Landes, 1994.
23.
Liu, H,
and
Maurice DH.
Expression of cyclic GMP-inhibited phosphodiesterase 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP.
Br J Pharmacol
125:
1501-1510,
1998[Web of Science][Medline].
24.
Murray, KJ.
Cyclic AMP and mechanisms of vasodilation.
Pharmacol Ther
47:
329-345,
1990[Web of Science][Medline].
25.
Nakanishi, S,
Kakita S,
Takahashi I,
Kawahara K,
Tsukuda E,
Sano T,
Yamada K,
Yoshida M,
Kase H,
and
Matsuda Y.
Wortmannin, a microbial product inhibitor of myosin light chain kinase.
J Biol Chem
267:
2157-2163,
1992
26.
Persechini, A,
Kamm KE,
and
Stull JT.
Different phosphorylated forms of myosin in contracting tracheal smooth muscle.
J Biol Chem
261:
6293-6299,
1986
27.
Rembold, CM,
Foster DB,
Strauss JD,
Wingard CJ,
and
Van Eyk JE.
cGMP-mediated phosphorylation of heat shock protein 20 may cause smooth muscle relaxation without myosin light chain dephosphorylation in swine carotid artery.
J Physiol (Lond)
524:
865-878,
2000
28.
Strauss, JD,
and
Murphy RA.
Regulation of cross-bridge cycling in smooth muscle.
In: Biochemistry of Smooth Muscle Contraction, edited by Barany M.. San Diego, CA: Academic, 1996, p. 341-353.
29.
Takata, M,
Ogawa W,
Kitamura T,
Hino Y,
Kuroda S,
Kotani K,
Klip A,
Gingras AC,
Sonenberg N,
and
Kasuga M.
Requirement for Akt (protein kinase B) in insulin-induced activation of glycogen synthase and phosphorylation of 4E-BP (PHAS-1).
J Biol Chem
274:
20611-20618,
1999
30.
Throckmorton, DC,
Packer CS,
and
Brophy CM.
Protein kinase C activation during Ca2+-independent vascular smooth muscle contraction.
J Surg Res
78:
48-53,
1998[Web of Science][Medline].
31.
Vlahos, CJ,
Matter WF,
Hui KY,
and
Brown RF.
Specific inhibitor of phosphatidylinositol 3-kinase, 2-morpholinyl -8-phenyl-4H-1-benzopyran-4-one (LY294002).
J Biol Chem
269:
5241-5248,
1994
32.
Wang, Y,
Xu A,
and
Cooper GJS
Phosphorylation of P20 is associated with the actions of insulin in rat skeletal and smooth muscle.
Biochem J
344:
971-976,
1999.
33.
Wang, Y,
Xu A,
Pearson RB,
and
Cooper GJS
Insulin and insulin antagonists evoke phosphorylation of P20 at serine 157 and serine 16 respectively in rat skeletal muscle.
FEBS Lett
462:
25-30,
1999[Web of Science][Medline].
34.
Whitney, G,
Throckmorton DC,
Isales C,
Takuwa Y,
Yeh J,
Rasmussen H,
and
Brophy CM.
Kinase activation and smooth muscle contraction in the presence and absence of calcium.
J Vasc Surg
22:
37-44,
1995[Web of Science][Medline].
35.
Wingard, CJ,
Browne AK,
and
Murphy RA.
Dependence of force on length at constant cross-bridge phosphorylation in the swine carotid media.
J Physiol (Lond)
488:
729-739,
1995
36.
Wingard, CJ,
and
Murphy RA.
Inhibition of Ca2+ -dependent contraction in swine carotid artery by myosin kinase inhibitors.
Gen Pharmacol
32:
483-494,
1999[Web of Science][Medline].
37.
Wingard, CJ,
Paul RJ,
and
Murphy RA.
Energetic cost of activation processes during contraction of swine arterial smooth muscle.
J Physiol (Lond)
501:
213-223,
1997
38.
Woodrum, DA,
Brophy CM,
Wingard CJ,
Beall A,
and
Rasmussen H.
Phosphorylation events associated with cyclic nucleotide-dependent inhibition of smooth muscle contraction.
Am J Physiol Heart Circ Physiol
277:
H931-H939,
1999
39.
Yeh, JL,
Whitney EG,
Lamb S,
and
Brophy CM.
Nitric oxide is an autocrine feedback inhibitor of vascular smooth muscle contraction.
Surgery
119:
104-109,
1996[Web of Science][Medline].
This article has been cited by other articles:
![]() |
Y. Cordeaux, H. Missfelder-Lobos, D. S. Charnock-Jones, and G. C. S. Smith Stimulation of Contractions in Human Myometrium by Serotonin is Unmasked by Smooth Muscle Relaxants Reproductive Sciences, September 1, 2008; 15(7): 727 - 734. [Abstract] [PDF] |
||||
![]() |
H. El-Haroun, D. L. Clarke, K. Deacon, D. Bradbury, A. Clayton, A. Sutcliffe, and A. J. Knox IL-1{beta}, BK, and TGF-{beta}1 attenuate PGI2-mediated cAMP formation in human pulmonary artery smooth muscle cells by multiple mechanisms involving p38 MAP kinase and PKA Am J Physiol Lung Cell Mol Physiol, March 1, 2008; 294(3): L553 - L562. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Braverman, A. S. Tibb, and M. R. Ruggieri Sr M2 and M3 Muscarinic Receptor Activation of Urinary Bladder Contractile Signal Transduction. I. Normal Rat Bladder J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 869 - 874. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. K. Misra and S. V. Pizzo Coordinate Regulation of Forskolin-induced Cellular Proliferation in Macrophages by Protein Kinase A/cAMP-response Element-binding Protein (CREB) and Epac1-Rap1 Signaling: EFFECTS OF SILENCING CREB GENE EXPRESSION ON Akt ACTIVATION J. Biol. Chem., November 18, 2005; 280(46): 38276 - 38289. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Jones and Y. Sharief Asymmetrical protein kinase A activity establishes neutrophil cytoskeletal polarity and enables chemotaxis J. Leukoc. Biol., July 1, 2005; 78(1): 248 - 258. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Budzyn, P. D. Marley, and C. G. Sobey Opposing Roles of Endothelial and Smooth Muscle Phosphatidylinositol 3-Kinase in Vasoconstriction: Effects of Rho-Kinase and Hypertension J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1248 - 1253. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Teng, W. Qin, H. R. Ansari, and S. J. Mustafa Involvement of p38-mitogen-activated protein kinase in adenosine receptor-mediated relaxation of coronary artery Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2574 - H2580. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Flynn, C. M. Brophy, E. J. Furnish, P. Komalavilas, D. Tessier, J. Thresher, and L. Joshi Transduction of phosphorylated heat shock-related protein 20, HSP20, prevents vasospasm of human umbilical artery smooth muscle J Appl Physiol, May 1, 2005; 98(5): 1836 - 1845. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Rubin, L. Magliola, X. Feng, A. W. Jones, and C. C. Hale Metabolic activation of AMP kinase in vascular smooth muscle J Appl Physiol, January 1, 2005; 98(1): 296 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Tolloczko, P. Turkewitsch, M. Al-Chalabi, and J. G. Martin LY-294002 [2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] Affects Calcium Signaling in Airway Smooth Muscle Cells Independently of Phosphoinositide 3-Kinase Inhibition J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 787 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Jackson, Z. Mi, and E. K. Jackson Modulation of Cyclic AMP Production by Signal Transduction Pathways in Preglomerular Microvessels and Microvascular Smooth Muscle Cells J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 349 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Wehrwein, C. A. Northcott, R. D. Loberg, and S. W. Watts Rho/Rho Kinase and Phosphoinositide 3-Kinase Are Parallel Pathways in the Development of Spontaneous Arterial Tone in Deoxycorticosterone Acetate-Salt Hypertension J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1011 - 1019. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Shi-Wen, Y. Chen, C. P. Denton, M. Eastwood, E. A. Renzoni, G. Bou-Gharios, J. D. Pearson, M. Dashwood, R. M. du Bois, C. M. Black, et al. Endothelin-1 Promotes Myofibroblast Induction through the ETA Receptor via a rac/Phosphoinositide 3-Kinase/Akt-dependent Pathway and Is Essential for the Enhanced Contractile Phenotype of Fibrotic Fibroblasts Mol. Biol. Cell, June 1, 2004; 15(6): 2707 - 2719. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Northcott, J. S. Hayflick, and S. W. Watts PI3-Kinase Upregulation and Involvement in Spontaneous Tone in Arteries From DOCA-Salt Rats: Is p110{delta} the Culprit? Hypertension, April 1, 2004; 43(4): 885 - 890. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Su, E. M. Smolock, K. N. Marcel, and R. S. Moreland Phosphatidylinositol 3-kinase modulates vascular smooth muscle contraction by calcium and myosin light chain phosphorylation-independent and -dependent pathways Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H657 - H666. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhang, N. Yang, D. Katsaros, W. Huang, J.-W. Park, S. Fracchioli, C. Vezzani, I. A. Rigault de la Longrais, W. Yao, S. C. Rubin, et al. The Oncogene Phosphatidylinositol 3'-Kinase Catalytic Subunit {alpha} Promotes Angiogenesis via Vascular Endothelial Growth Factor in Ovarian Carcinoma Cancer Res., July 15, 2003; 63(14): 4225 - 4231. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Loberg, C. A. Northcott, S. W. Watts, and F. C. Brosius III PI3-Kinase-Induced Hyperreactivity in DOCA-Salt Hypertension Is Independent of GSK-3 Activity Hypertension, April 1, 2003; 41(4): 898 - 902. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Northcott, M. N. Poy, S. M. Najjar, and S. W. Watts Phosphoinositide 3-Kinase Mediates Enhanced Spontaneous and Agonist-Induced Contraction in Aorta of Deoxycorticosterone Acetate-Salt Hypertensive Rats Circ. Res., August 23, 2002; 91(4): 360 - 369. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |